(Q34938155)

5 August 2017

A phase II study of the gamma secretase inhibitor RO4929097 in patients with previously treated metastatic pancreatic adenocarcinoma (English)

1 reference

pancreatic adenocarcinoma

5 August 2017

1 reference

1 reference

based on heuristic

inferred from title

metastatic pancreatic adenocarcinoma

1 reference

3

Anirban Maitra

1 reference

5 August 2017

Ana De Jesus-Acosta

1

1 reference

5 August 2017

Daniel Laheru

2

1 reference

5 August 2017

John Arcaroli

4

1 reference

5 August 2017

Michelle A Rudek

5

1 reference

5 August 2017

Arvind Dasari

6

1 reference

5 August 2017

Patrick J Blatchford

7

1 reference

5 August 2017

Kevin Quackenbush

8

1 reference

5 August 2017

Wells Messersmith

9

1 reference

5 August 2017

27 March 2014

1 reference

Investigational New Drugs

5 August 2017

1 reference

5 August 2017

32

1 reference

5 August 2017

4

1 reference

5 August 2017

739-745

1 reference

https://scigraph.springernature.com/pub.10.1007/s10637-014-0083-8

5 August 2017

0 references

cites work

Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4292847

A phase I study of the combination of ro4929097 and cediranib in patients with advanced solid tumours (PJC-004/NCI 8503).

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4292847

A phase Ib combination study of RO4929097, a gamma-secretase inhibitor, and temsirolimus in patients with advanced solid tumors

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4292847

A phase I study of the oral gamma secretase inhibitor R04929097 in combination with gemcitabine in patients with advanced solid tumors (PHL-078/CTEP 8575).

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4292847

Phase I study of RO4929097, a gamma secretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumors

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4292847

A phase II study of RO4929097 in metastatic colorectal cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4292847

FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4292847

Validation and implementation of a liquid chromatography/tandem mass spectrometry assay for quantitation of the total and unbound RO4929097, a γ-secretase inhibitor targeting Notch signaling, in human plasma

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4292847

TW-37, a small-molecule inhibitor of Bcl-2, inhibits cell growth and induces apoptosis in pancreatic cancer: involvement of Notch-1 signaling pathway

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4292847

Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4292847

Ligand-dependent Notch signaling is involved in tumor initiation and tumor maintenance in pancreatic cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4292847

Inhibition of gamma-secretase activity inhibits tumor progression in a mouse model of pancreatic ductal adenocarcinoma

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4292847

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4292847

Developmental biology of the pancreas: a comprehensive review

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4292847

Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4292847

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4292847

Notch and Kras in pancreatic cancer: at the crossroads of mutation, differentiation and signaling

8 July 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS10637-014-0083-8

Essential role of Notch signaling in apoptosis of human pancreatic tumoral cells mediated by exosomal nanoparticles.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS10637-014-0083-8

Notch mediates TGF alpha-induced changes in epithelial differentiation during pancreatic tumorigenesis

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24668033

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S10637-014-0083-8

1 reference

Dimensions Publication ID

5 August 2017

0 references

1 reference

5 August 2017

1 reference